These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30904558)

  • 21. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
    Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
    Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date.
    Dani SS; Ganatra S; Vaduganathan M
    Int J Cardiol; 2021 Jan; 323():188-191. PubMed ID: 32841619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-Life Indications to Sacubitril/Valsartan Treatment in Patients With Chronic Systolic Heart Failure.
    Pinto G; Tondi L; Gemma M; De Marco A; Silipigni C; Spoladore R; Margonato A; Fragasso G
    J Cardiovasc Pharmacol; 2019 May; 73(5):301-306. PubMed ID: 30855406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).
    Vardeny O; Claggett B; Kachadourian J; Pearson SM; Desai AS; Packer M; Rouleau J; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    Circ Heart Fail; 2018 Apr; 11(4):e004745. PubMed ID: 29643067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
    N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Sacubitril-Valsartan on Markers of Glomerular Function.
    Tersalvi G; Dauw J; Martens P; Mullens W
    Curr Heart Fail Rep; 2020 Aug; 17(4):145-152. PubMed ID: 32488503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Three case reports of involuntary muscular movements as adverse reactions to sacubitril/valsartan.
    Bejan-Angoulvant T; Genet T; Vrignaud L; Angoulvant D; Fauchier L
    Br J Clin Pharmacol; 2018 May; 84(5):1072-1074. PubMed ID: 29512176
    [No Abstract]   [Full Text] [Related]  

  • 29. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
    Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
    JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
    Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
    Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.
    Yandrapalli S; Andries G; Biswas M; Khera S
    Vasc Health Risk Manag; 2017; 13():369-382. PubMed ID: 29042791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety of sacubitril-valsartan for the treatment of chronic heart failure.
    Tyler JM; Teerlink JR
    Expert Opin Drug Saf; 2017 Feb; 16(2):257-263. PubMed ID: 28060547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
    McCormack PL
    Drugs; 2016 Mar; 76(3):387-96. PubMed ID: 26873495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
    Lillyblad MP
    Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serious adverse drug reactions with sacubitril/valsartan Entresto®: a French pharmacovigilance survey.
    Moulis F; Rousseau V; Chebane L; Gouverneur A; Gaboriau L; Faillie JL; Durrieu G; Montastruc F; Montastruc JL
    Eur J Clin Pharmacol; 2018 Jul; 74(7):983-984. PubMed ID: 29656309
    [No Abstract]   [Full Text] [Related]  

  • 37. In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitors-The Time Is Now.
    Srivastava PK; Fonarow GC
    JAMA Cardiol; 2019 Mar; 4(3):195-196. PubMed ID: 30810709
    [No Abstract]   [Full Text] [Related]  

  • 38. Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.
    Liu RC
    Am J Cardiovasc Drugs; 2018 Dec; 18(6):473-482. PubMed ID: 29850980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sacubitril-valsartan: novel therapy for heart failure.
    Sehn E; McDonald T; Lindblad AJ
    Can Fam Physician; 2017 Sep; 63(9):697. PubMed ID: 28904036
    [No Abstract]   [Full Text] [Related]  

  • 40. Insights into implementation of sacubitril/valsartan into clinical practice.
    Martens P; Beliën H; Dupont M; Mullens W
    ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.